Efficacy of SMOF Lipid in the Management of Acute Poisoning With Carbamazepine

Launched by ALEXANDRIA UNIVERSITY · Mar 14, 2024

Keywords

ClinConnect Summary

Among anticonvulsants, carbamazepine (CBZ) is considered one of the most commonly reported poisonings. Carbamazepine (CBZ) was approved for use as a primary anticonvulsant agent following its initial use for trigeminal neuralgia. Further indications for the drug included treatment for bipolar disorder, resistant schizophrenia, and pain syndromes.

The wide availability of carbamazepine increases the potential for overdose, either accidentally or intentionally. The American Association of Poison Control Centres reported 2,562 hazardous exposures to CBZ in 2020. In addition, CBZ was the most ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• The patients were enrolled in the study in accordance with the following:
• • 1. Gender and age: adult symptomatic males and females.
• • 2. Patients were admitted within 12 hours of exposure to the poison.
• • 3. Patients received no prior treatment before admission.
• • 4. Patients with moderate-to-severe carbamazepine poisoning according to the Poisoning Severity Score (PSS)
• • 5. Patients classified as high-risk (HR) with anti-depressant overdose risk assessment (ADORA) criteria.
• Exclusion Criteria:
• Patients will be excluded if they have any of the following conditions:
• • 1. pregnant and lactating women.
• • 2. Patients with major medical conditions (e.g. diabetes mellitus), cardiovascular disease, renal, or hepatic failure).
• • 3. Patients suffering from hyperlipidemia.
• • 4. Malignancy.
• • 5. Co-ingestion.